Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus PERMITIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus PERMITIL.
MELLARIL vs PERMITIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Antagonist at dopamine D2 receptors, also blocks alpha-1 adrenergic, histaminergic, and muscarinic receptors.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
2.5-10 mg orally every 8-12 hours; maximum 40 mg/day. For severe psychosis: initial 10 mg IM, then 5-10 mg IM every 6-8 hours; maximum 30 mg/day IM.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Terminal elimination half-life: 20-30 hours; clinically, steady-state achieved in 5-7 days; prolonged in elderly and hepatic impairment
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Renal: <1% unchanged; Hepatic: extensively metabolized, metabolites excreted in urine (50-60%) and feces (30-40%)
Category C
Category C
Antipsychotic
Antipsychotic